NEW YORK, Jan 2 - Biogen will use MorphoSys' Human Combinatorial Antibody Library technology to validate drug targets in its genomics programs, MorphoSys announced Tuesday.
Under the terms of the agreement, Biogen will pay MorphoSys an upfront technology access fee and for use of MorphoSys' HuCAL technology for generating antibodies against expressed sequence tags, and will provide its own R & D funding. Biogen will make milestone and royalty payments to MorphoSys for any antibody-based therapeutics developed.
Financial terms of the agreement were not disclosed.
" This collaboration highlights the power of the MorphoSys technologies as tools for genomics-driven pharmaceutical discovery," Simon Moroney, MorphoSys CEO, said in a statement. " This deal is yet another example of our strategy of leveraging HuCAL as a tool to accelerate the identification of new targets. "
MorphoSys’ HuCAL technology produces synthetic human antibodies used in drug discovery. The company has licensing and research collaborations with Bayer, Roche AG, DuPont Pharmaceuticals, Millennium, Chiron, GPC Biotech AG, ProChon Biotech, Eos Biotechnology, and ImmunoGen.